Literature DB >> 22237674

Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies.

Nikolaos Papathanasiou1, Phivi Rondogianni, Panagiota Chroni, Marios Themistocleous, Efstathios Boviatsis, Xanthi Pedeli, Damianos Sakas, Ioannis Datseris.   

Abstract

OBJECTIVE: To evaluate the degree of interobserver agreement in the visual interpretation of (123)I-FP-CIT studies and to investigate for potential associations between visual and semi-quantitative parameters.
METHODS: Eighty-nine (123)I-FP-CIT studies were blindly reviewed by 3 independent observers: a consultant, a resident doctor and a radiographer. They classified every study as either "normal" or "abnormal" and assigned visual (123)I-FP-CIT uptake scores (2: normal, 1: reduced and 0: no uptake) in basal ganglia nuclei (right and left putamina and caudate nuclei) on every scan. Striatal (123)I-FP-CIT binding ratios were calculated using crescent-ROI software. The interobserver agreement for the interpretation of studies and for visual score assignment was evaluated by means of κ statistics. We investigated for associations of binding ratios with visual scores and clinical parameters; patients' clinical diagnoses served as the reference standard.
RESULTS: There was excellent interobserver agreement (κ 0.89-0.93) in classifying studies as "normal" or "abnormal" and fine agreement in assignment of visual scores (κ 0.71-0.80 for putamina and 0.50-0.79 for caudate nuclei). Nuclei with scores of 1 and 0 showed significantly reduced binding ratios (about 30 and 50%, respectively) compared with the nuclei scored as 2. ROC analysis indicated the optimal cutoff point of striatal binding ratio at 3.8 (sensitivity 98.5%, specificity 95%) for the detection of parkinsonian syndromes. Striatal binding ratios were negatively associated with age in normal subjects and disease duration in Parkinson's disease patients.
CONCLUSION: Visual interpretation of (123)I-FP-CIT studies showed very good interobserver agreement. We found significant associations among visual, semi-quantitative and clinical parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237674     DOI: 10.1007/s12149-011-0564-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

2.  Dopaminergic imaging separates normal pressure hydrocephalus from its mimics.

Authors:  Gilles Allali; Valentina Garibotto; Ismini C Mainta; Nicolas Nicastro; Frederic Assal
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

3.  Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.

Authors:  Moonyoung Chung; Young Seok Park; Ji Seon Kim; Yun Joong Kim; Hyeo Il Ma; Su Jin Jang; Ryoong Huh; Hyun Sook Kim; Won-Chan Kim
Journal:  Jpn J Radiol       Date:  2015-05-08       Impact factor: 2.374

4.  Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.

Authors:  Jun Ueda; Hajime Yoshimura; Keiji Shimizu; Megumu Hino; Nobuo Kohara
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

5.  Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.

Authors:  Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

6.  Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Katrine Riklund
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

7.  Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.

Authors:  John T O'Brien; Wolfgang H Oertel; Ian G McKeith; Donald G Grosset; Zuzana Walker; Klaus Tatsch; Eduardo Tolosa; Paul F Sherwin; Igor D Grachev
Journal:  BMJ Open       Date:  2014-07-03       Impact factor: 2.692

8.  Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging.

Authors:  Hongyoon Choi; Seunggyun Ha; Hyung Jun Im; Sun Ha Paek; Dong Soo Lee
Journal:  Neuroimage Clin       Date:  2017-09-10       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.